Literature DB >> 31160300

Unexpected benefit from an 'old' metronomic chemotherapy regimen in advanced chordoma.

Mariella Spalato Ceruso1, Andrea Napolitano1, Marianna Silletta1, Bruno Vincenzi1.   

Abstract

In this case report, we describe an older adult man affected by advanced chordoma progressing after treatment with cisplatin and imatinib. The patient was symptomatic for uncontrolled pain. We decided to treat the patient with metronomic cyclophosphamide, unexpectedly achieving long-lasting clinical and radiological benefit. © BMJ Publishing Group Limited 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  chemotherapy; geriatric medicine; oncology

Mesh：

Substances：

Year:  2019        PMID： 31160300      PMCID： PMC6557366          DOI： 10.1136/bcr-2018-228728

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN： 1757-790X


  9 in total

1.  Metronomic oral cyclophosphamide prednisolone chemotherapy is an effective treatment for metastatic hormone-refractory prostate cancer after docetaxel failure.

Authors:  Sylvain Ladoire; Jean Christophe Eymard; Sylvie Zanetta; Grégoire Mignot; Etienne Martin; Isabelle Kermarrec; Eric Mourey; Frédéric Michel; Luc Cormier; François Ghiringhelli
Journal:  Anticancer Res       Date:  2010-10       Impact factor: 2.480

2.  "Metronomic" chemotherapy in advanced soft tissue sarcomas.

Authors:  Antoine Italiano; Maud Toulmonde; Barbara Lortal; Eberhard Stoeckle; Delphine Garbay; Guy Kantor; Michèle Kind; Jean-Michel Coindre; Binh Bui
Journal:  Cancer Chemother Pharmacol       Date:  2010-02-25       Impact factor: 3.333

3.  Feasibility of metronomic oral cyclophosphamide plus prednisolone in elderly patients with inoperable or metastatic soft tissue sarcoma.

Authors:  Olivier Mir; Julien Domont; Angela Cioffi; Sylvie Bonvalot; Bérénice Boulet; Cécile Le Pechoux; Philippe Terrier; Marc Spielmann; Axel Le Cesne
Journal:  Eur J Cancer       Date:  2011-01-19       Impact factor: 9.162

4.  Long-term Efficacy of Methotrexate Plus Vinblastine/Vinorelbine in a Large Series of Patients Affected by Desmoid-Type Fibromatosis.

Authors:  Elena Palassini; Anna Maria Frezza; Luigi Mariani; Luca Lalli; Chiara Colombo; Marco Fiore; Antonella Messina; Alessandra Casale; Carlo Morosi; Paola Collini; Silvia Stacchiotti; Paolo Giovanni Casali; Alessandro Gronchi
Journal:  Cancer J       Date:  2017 Mar/Apr       Impact factor: 3.360

5.  Imatinib in advanced chordoma: A retrospective case series analysis.

Authors:  Nadia Hindi; Paolo G Casali; Carlo Morosi; Antonella Messina; Elena Palassini; Silvana Pilotti; Elena Tamborini; Stefano Radaelli; Alessandro Gronchi; Silvia Stacchiotti
Journal:  Eur J Cancer       Date:  2015-08-14       Impact factor: 9.162

6.  A dose-escalating phase I of imatinib mesylate with fixed dose of metronomic cyclophosphamide in targeted solid tumours.

Authors:  A Adenis; I Ray-Coquard; A Italiano; E Chauzit; B Bui-Nguyen; J-Y Blay; E Tresch-Bruneel; C Fournier; S Clisant; E Y Amela; P A Cassier; M Molimard; N Penel
Journal:  Br J Cancer       Date:  2013-10-22       Impact factor: 7.640

7.  Low dose metronomic oral cyclophosphamide for hormone resistant prostate cancer: a phase II study.

Authors:  R Lord; S Nair; A Schache; J Spicer; Navita Somaihah; V Khoo; H Pandha
Journal:  J Urol       Date:  2007-06       Impact factor: 7.450

8.  Molecular Targeted Therapy in the Treatment of Chordoma: A Systematic Review.

Authors:  Tong Meng; Jiali Jin; Cong Jiang; Runzhi Huang; Huabin Yin; Dianwen Song; Liming Cheng
Journal:  Front Oncol       Date:  2019-02-01       Impact factor: 6.244

Review 9.  Metronomic chemotherapy.

Authors:  Rituparna Maiti
Journal:  J Pharmacol Pharmacother       Date:  2014-07
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.